Literature DB >> 22653706

Thromboprophylaxis in major knee and hip replacement surgery: a review.

Gonzalo Eymin1, Amir K Jaffer.   

Abstract

Patients undergoing total knee and total hip replacement (THR/TKR) surgery are at high risk of venous thromboembolism (VTE), and routine thromboprophylaxis is recommended after these procedures. However, current thromboprophylaxis may require daily injections, careful anticoagulation monitoring, and dietary restrictions, which can lead to poor patient compliance and suboptimal outcomes. Therefore, there is an unmet need for simpler medication options. Newer oral anticoagulants have improved efficacy over standard treatments, with convenient dosing regimens, more predictable pharmacologic profiles that reduce the need for anticoagulation monitoring, and fewer drug or food interactions. These drugs have the potential to simplify anticoagulation after THR or TKR surgery, which may lead to improved adherence, thus lowering the incidence of VTE and associated complications after surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653706     DOI: 10.1007/s11239-012-0751-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  41 in total

Review 1.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

2.  Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

Authors:  R J Friedman; O E Dahl; N Rosencher; J A Caprini; A A Kurth; C W Francis; A Clemens; S Hantel; J M Schnee; B I Eriksson
Journal:  Thromb Res       Date:  2010-05-15       Impact factor: 3.944

3.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

4.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

5.  Heparin-induced thrombocytopenia from venous thromboembolism treatment.

Authors:  S M Begelman; M J Hursting; R V Aghababian; D McCollum
Journal:  J Intern Med       Date:  2005-12       Impact factor: 8.989

Review 6.  Risk factors for venous thromboembolism after total hip and knee replacement surgery.

Authors:  Richard H White; Mark C Henderson
Journal:  Curr Opin Pulm Med       Date:  2002-09       Impact factor: 3.155

7.  Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.

Authors:  Maureen A Smythe; Theodore E Warkentin; Jennifer L Stephens; Dana Zakalik; Joan C Mattson
Journal:  Am J Hematol       Date:  2002-09       Impact factor: 10.047

8.  Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial.

Authors:  P L Chin; M S Amin; K Y Yang; S J Yeo; N N Lo
Journal:  J Orthop Surg (Hong Kong)       Date:  2009-04       Impact factor: 1.118

9.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

10.  Long-term complications of medical patients with hospital-acquired venous thromboembolism.

Authors:  John Fanikos; Gregory Piazza; Maksim Zayaruzny; Samuel Z Goldhaber
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

View more
  1 in total

1.  Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs.

Authors:  Noelle D Herrera; Ingvild Birschmann; Monika Wolny; Mark G Papich; Marjory B Brooks; Robert Goggs
Journal:  Front Vet Sci       Date:  2021-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.